



EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

emu™ REGIONAL BENEFITS STUDY ADVANCING, CRC-P PROGRESS PAYMENT RECEIVED

Key Highlights

- **Site visits completed and protocol advancing for CRC-P funded Regional Benefits Study, designed to generate clinical benefits evidence for the regional and remote use case of the emu™ bedside scanner.**
- **Study targets regional and remote hospitals without ready CT access, where suspected stroke patients must typically be transferred, sometimes many hours by road or air, before diagnosis is possible.**
- **Workflow design well advanced alongside South Australia's telestroke service to integrate emu™ into regional care pathways.**
- **The regional use case addresses a global need, beginning with ~400 rural, regional and remote hospitals in Australia and over 1,300 US Critical Access Hospitals. Similar models of care and similar diagnostic challenges are found across rural communities worldwide.**
- **Cooperative Research Centres Projects (CRC-P) progress payment of \$337,425 received.**
- **Next steps include protocol finalisation, ethics approval, site contracting and research governance approvals. Additional sites are also under consideration.**

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company") is pleased to provide an update on preparations for its Regional Benefits Study, grant funded under the Australian Government's Cooperative Research Centres Projects (CRC-P) program.

Under this CRC-P project, a clinical study in South Australian regional hospitals will be conducted with EMVision's emu™ bedside brain scanner, with telehealth and specifically trained nurses, to demonstrate the ability to provide more timely stroke diagnosis. CRC-P project partners include the Australian Stroke Alliance, Titan Pre-Hospital Innovation and South Australia's Rural Support Service.

The study is intended to generate benefits data for the regional use case of the emu™, one of many use cases for the device, to help support clinical adoption in settings where timely access to CT is limited or unavailable. This is the first study to evaluate the benefit of the emu™ in clinical use.

Site visits have been completed, protocol and ethics preparation are well advanced, and a CRC-P progress payment of \$337,425 was received in August 2026.

Site Visits

The EMVision team completed site visits at two remote emergency departments in regional South Australia. Both sites employ nurse-led emergency assessment models without on-site CT and varying degrees of supporting medical coverage. Suspected stroke patients cannot currently be diagnosed locally and must be transferred to a larger hospital before a diagnosis can be confirmed and subsequent treatment decisions made. One of the sites is among the most isolated hospitals in the state, with the nearest comprehensive stroke centre approximately eight hours away by road, or around 1.5 hours by air.

During the site visits, the respective teams worked through the practical details of an emu™ enabled workflow with local staff, including how a suspected stroke patient enters the emergency department and is assessed, and how an emu™ scan would fit alongside the existing telestroke consultation and retrieval processes.

The study represents a potential paradigm shift for participating hospitals, from refining stroke care workflows focused on identifying transfer candidates to adding diagnostic capabilities to identify patients eligible for treatment prior to being transferred. These workflows will also enhance EMVision's understanding of how a bedside neurodiagnostic device is used in non-specialist and remote settings.

Protocol, telestroke integration and next steps

Study protocol drafting is in progress. EMVision is liaising with South Australia's telestroke service to establish appropriate practices for an emu™ enabled workflow at the investigational sites and to determine how the device integrates with existing stroke pathways. Following protocol finalisation, the Company intends to integrate emu™ via telehealth so that scan results are available to the consulting stroke neurologist as part of the standard consultation.

Next steps include protocol finalisation, ethics approval, site contracting and research governance approvals. The inclusion of additional sites under the study is also being considered. EMVision will provide further updates as these milestones are achieved.

Relevance to the US Critical Access Hospital market

The South Australian sites participating in the study share a similar model of care to the Critical Access Hospitals (CAHs) in the United States. CAHs are federally designated rural hospitals of no more than 25 beds, located more than 35 miles from another hospital and required to provide 24-hour emergency care. Access to the necessary tools to diagnose stroke and stroke type is inconsistent, with a national analysis finding that only 56% of US states have some form of CT imaging available at every CAH in that state. Even where a CT scanner is present, around the clock technologist coverage to run the CT cannot be assured and the advanced imaging (CTA, CTP or MRI) needed to positively identify acute ischaemia and guide decision making is frequently unavailable. In addition, stroke mortality in the most rural US counties is approximately 30% higher than in large metropolitan areas. As a result, EMVision expects the experience and evidence generated in the Regional Benefits Study to be highly relevant to the US regional opportunity and to inform the design of subsequent US-based benefits work with US clinical collaborators.

Commercially, CAHs are reimbursed by Medicare at 101% of reasonable costs, a cost-based model that may lower the barrier to adopting capital equipment where clinical and operational benefit is demonstrated. EMVision has previously identified approximately 330 CAHs within the US 'Stroke Belt' as high-priority targets for initial US launch. Evidence regarding the ability of the emu™ to support timelier and more efficient triage, transfer or treatment decisions in these rural, regional and remote settings is critical for hospital procurement and health system adoption.

EMVision CEO and Managing Director Scott Kirkland commented, "Stroke outcomes for people in rural, regional and remote Australia are significantly worse than for those in our cities. This is an inequity that is mirrored in many rural communities worldwide. This study is designed to show the benefit of moving the diagnosis to the patient, speeding up time-sensitive clinical decisions, starting in some of the most remote hospitals in Australia, with clear relevance to rural America."

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

About Stroke

Stroke is a medical emergency that occurs when blood flow to part of the brain is interrupted, either by a blocked vessel (ischaemic stroke) or bleeding into the brain (hemorrhagic stroke). The resulting lack of oxygen and nutrients can rapidly damage brain tissue, leading to disability or death if not treated promptly. Different stroke types require different types of care. Early recognition and fast access to diagnosis and appropriate care are critical, as timely intervention can significantly improve outcomes.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.